Company: PSTV
Filing Date: 2025-07-11
Form Type: PRE 14A
Source: 0001140361-25-025650
Chunk: 76

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-11
Form: PRE 14A
Chunk 76
---
 49

TABLE OF CONTENTS

PROPOSAL 5—PROPOSAL TO APPROVE THE FIFTH AMENDMENT AND RESTATEMENT OF THE 2020 STOCK INCENTIVE PLAN On [•], 2025, our Board, upon recommendation of the Compensation Committee, approved the fifth amendment and restatement of our 2020 Stock Incentive Plan (the “Fifth Amended Plan”), subject to the approval of our stockholders at the Annual Meeting. The 2020 Stock Incentive Plan was approved by our stockholders at our 2020 annual meeting of stockholders. Subsequently, the amended and restated 2020 Stock Incentive Plan was approved by our stockholders at our 2021 annual meeting of stockholders, the second amended and restated 2020 Stock Incentive Plan was approved by our stockholders at our 2022 annual meeting of stockholders, the third amended and restated 2020 Stock Incentive Plan was approved by our stockholders at our 2023 annual meeting of stockholders, and the fourth amended and restated 2020 Stock Incentive Plan was approved by our stockholders at our 2024 annual meeting of stockholders (collectively referred to as the “Plan” in this proposal). The Board is requesting stockholder approval of the Fifth Amended Plan. The Board believes that equity awards are a key element underlying its ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully and implement our growth plans. After reviewing the 2020 Plan, the Board has determined that the current share reserve available for awards under the 2020 Plan is insufficient and limits the Board’s ability to provide equity incentives that align the interests of our directors, executives and employees with those of our stockholders and limits our ability to attract and retain talented personnel. Approval of the Fifth Amended Plan by our stockholders will allow us to grant stock options, restricted stock unit awards and other awards at levels determined appropriate by our Board or Compensation Committee. The Fifth Amended Plan contains the following material changes from the Plan:

| • | Subject to adjustment for certain changes in our capitalization, the maximum aggregate number of shares of our Common Stock that may be issued under the Fifth Amended Plan is increased by 20,000,000 shares. |

| • | Subject to adjustment for certain changes in our capitalization, the number of shares of our Common Stock issuable under the Fifth Amended Plan as incentive stock options (“